Trametinib is an orally active diaryl-anilide that allosterically blocks mitogen-activated protein kinase kinase-1 and -2 at sub-nanomolar potency, inducing autophagy and apoptosis to curb proliferation in RAS/RAF-driven tumors.
Usually ships within 24 hours.